What Ocular Therapeutix, Inc does.

We are an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI, also known as OTX-TKI, our investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on our ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently being evaluated in a Phase 3 registrational program for wet age-related macular degeneration, or wet AMD, which we refer to as the SOL program. AXPAXLI is currently also being evaluated in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, or NPDR, which we refer to as the HELIOS program.

We also leverage the ELUTYX technology in our commercial product DEXTENZA, a corticosteroid approved by the U.S. Food and Drug Administration, or FDA, for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and for the treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in our product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma, or OAG, or ocular hypertension, or OHT. We are currently evaluating next steps for the OTX-TIC program.

Revenue and profit, by fiscal year.

More on OCUL.

• Ocular Therapeutix, Inc summary
• Ocular Therapeutix, Inc financial statements
• Ocular Therapeutix, Inc key metrics
• Ocular Therapeutix, Inc health scores and style box
• Ocular Therapeutix, Inc earnings
• Ocular Therapeutix, Inc dividends
• Ocular Therapeutix, Inc valuation
• Ocular Therapeutix, Inc ownership and insiders
• Ocular Therapeutix, Inc peers

Figures from Ocular Therapeutix, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.